0001104659-26-016476
SEC filingNanoViricides, Inc. reported a net loss of $2.2 million for Q2 2026 (period ending December 31, 2025), consistent with its operating loss of $2.2 million. The company generated no revenue during the quarter. Operating expenses totaled $2.2 million, evenly split between research and development ($1.1 million) and general and administrative costs ($1.1 million). The company reported minimal other income of $12,000 from interest, partially offset by $149 in interest expense. The balance sheet shows total assets of $12.3 million, with cash and equivalents of $5.2 million and property/equipment net of $6.7 million. Total liabilities were $1.2 million, resulting in stockholders' equity of $11.1 million. Cash flow from operations was negative $4.8 million, while financing activities provided $7.3 million primarily from stock sales, resulting in a net cash increase of $3.6 million. The company continues to operate as a development-stage biotechnology company with significant accumulated deficit of $152.8 million.
NanoViricides reported a net loss of $2.2 million for the second quarter of fiscal year 2026 (period ending December 31, 2025), which equals its operating loss of $2.2 million. The company generated no revenue during the quarter. Operating expenses totaled $2.2 million, comprising research and development expenses of $1.1 million and general and administrative expenses of $1.1 million. Other income was minimal at $12,000 from interest income, partially offset by $149 in interest expense. The company reported basic and diluted net loss per share of $0.00 with weighted average common shares outstanding of 19.9 million for both basic and diluted calculations. No prior period comparisons are provided in the available data.
No revenue was generated during the quarter, consistent with the company's status as a development-stage biotechnology company. The filing contains no segment breakdown, geographic mix, or revenue growth drivers as the company has not yet commercialized any products. All financial activity relates to research and development operations and corporate administrative functions.
With no revenue generated, gross margin and operating margin calculations are not applicable. The company's cost structure shows equal allocation between research and development ($1.1 million) and general and administrative expenses ($1.1 million). The operating loss margin is 100% of operating expenses due to zero revenue. The net loss margin similarly reflects 100% of total expenses offset only by minimal other income of $12,000.
Cash flow from operating activities was negative $4.8 million, driven by a net loss of $4.0 million adjusted for non-cash items including stock-based compensation ($246,000), depreciation ($131,000), and amortization ($2,000). Investing activities used $84,000 for property and equipment purchases. Financing activities provided $7.3 million from net proceeds of common stock and warrant sales. The net cash increase was $3.6 million, ending with cash and equivalents of $5.2 million. The balance sheet shows total assets of $12.3 million, including property and equipment net of $6.7 million and intangible assets of $313,000. Total liabilities are $1.2 million, with stockholders' equity of $11.1 million reflecting additional paid-in capital of $163.9 million offset by accumulated deficit of $152.8 million.
The filing contains no specific management guidance, strategic priorities, or forward-looking statements in the provided content. As a development-stage company, NanoViricides continues to focus on research and development activities. The company's ability to continue operations depends on its ability to obtain additional financing, as indicated by the $7.3 million raised through stock sales during the quarter. No specific risk factors or future projections are disclosed in the provided document sections.